Merck & Co Inc (MRK)
87.70
-0.69 (-0.78%)
USD |
NYSE |
Oct 06, 10:34
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 222.17B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 12.09% |
| Valuation | |
| PE Ratio | 13.43 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.893 |
| Price to Book Value | 5.138 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.69 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7322 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 27.26% |
News
Headline
Wire
Time (ET)
SA Breaking News
10/06 05:10
MT Newswires
10/04 16:27
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 10/27/2022 | -- | Results | Q3 2022 | -- | 1.75 | -- | |
| 10/27/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 07/28/2022 | -- | Results | Q2 2022 | 1.87 | 1.71 | 9.57% | |
| 07/28/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 04/28/2022 | -- | Results | Q1 2022 | 2.14 | 1.83 | 17.11% | |
| 04/28/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/03/2022 | -- | Results | Q4 2021 | 1.80 | 1.52 | 18.08% | |
| 02/03/2022 | 08:00 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States. |
| URL | https://www.merck.com |
| Investor Relations URL | https://www.merck.com/investor-relations |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Oct. 27, 2022 |
| Last Earnings Release | Jul. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 14, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 2.72 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 2.126 |
| Yield to Sector | 1.692 |
| Yield to Industry | 0.8445 |
| Last Dividend Amt. | 0.69 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | Sep. 14, 2022 |
| Yield (TTM) | 3.15% |
| Forward Yield | 3.12% |
| Payout Ratio | 41.06% |
| Cash Payout Ratio | 47.28% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of October 05, 2022.
Fundamentals
| Revenue (TTM) | 57.17B |
| Total Expenses (TTM) | 37.81B |
| Net Income (TTM) | 16.58B |
| Total Assets (Quarterly) | 107.10B |
| Total Liabilities (Quarterly) | 63.78B |
| Shareholders Equity (Quarterly) | 43.24B |
| Cash from Operations (TTM) | 18.89B |
| Cash from Investing (TTM) | -15.36B |
| Cash from Financing (TTM) | -1.93B |
Ratings
Profile
Edit
| Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States. |
| URL | https://www.merck.com |
| Investor Relations URL | https://www.merck.com/investor-relations |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Oct. 27, 2022 |
| Last Earnings Release | Jul. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 14, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| XLV | 1.758B USD | 4.70% |
| SCHD | 1.561B USD | 4.19% |
| VHCIX | 732.89M USD | 3.94% |
| VEIPX | 1.262B USD | 2.51% |
| GEQAX | 721.35M USD | 2.02% |
| MEIGX | 967.34M USD | 1.66% |
| VHYAX | 917.34M USD | 1.58% |
| VYM | 917.34M USD | 1.58% |
| VIVAX | 1.889B USD | 1.31% |
| VTV | 1.889B USD | 1.31% |
| IVV | 1.951B USD | 0.72% |
| SPY | 2.436B USD | 0.70% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| MRK Tweets |